Disease-Focused Discovery
PureTech established the underlying programs and platforms that resulted in a substantial pipeline comprised of 24 products and product candidates that are being advanced both internally and through PureTech's Founded Entities, including two products that have been cleared by the FDA.
View our corporate deck.
PureTech's Components of Value
Wholly Owned Pipeline
1 | Lymphatic flow disorders, incl. lymphedema | ~1M |
Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).
1 | COVID-19 post-recovery respiratory complications |
Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).
1 | Other fibrotic & inflammatory disorders | ~130K (IPF or uILD) |
Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).
Preclinical | Solid tumors | 57K/year (Pancreatic cancer) |
LYT-200 is an investigational, fully human, IgG4 monoclonal antibody (mAb) that is designed to target galectin-9, a protein that regulates immunosuppression and is prominently expressed in hard-to-treat cancers, such as colorectal cancer, or CRC, cholangiocarcinoma, pancreatic cancer and others.
Preclinical | Solid tumors | 57K/year (Pancreatic Cancer) |
LYT-210 is an investigational, fully human IgG1 monoclonal antibody (mAb) directed against the delta-1 (γδ1) chain of T cells bearing γδ1 T cell receptors (TCRs) for antibody dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis (ADCP).
Preclinical | GI autoimmunity | 57K/year (Pancreatic Cancer) |
LYT-210 is an investigational, fully human IgG1 monoclonal antibody (mAb) directed against the delta-1 (γδ1) chain of T cells bearing γδ1 T cell receptors (TCRs) for antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis (ADCP).
neurological indications
A synthetic lymphatic targeting chemistry platform being developed to employ the body’s natural lipid absorption and transport process to orally administer drugs via the lymphatic system by (1) targeting the mesenteric lymph nodes and (2) bypassing first-pass metabolism.
A milk exosome-based technology being developed to enable oral administration of macromolecule therapeutic payloads, including antisense oligonucleotides, short interfering RNA, messenger RNA (mRNA), peptides and nanoparticles that are otherwise administered exclusively by injection.
A platform that aims to correct lymphatic dysfunction in the brain to potentially improve outcomes for a range of neurodegenerative and neuroinflammatory conditions that are not currently effectively treated, such as Alzheimer’s disease and Parkinson’s disease.
| Phase completed | Phase in progress |
Founded Entities
$666.8m
Secured for Founded Entities in 2019, 93.4% from Third Parties1
Controlling Interest or Right to Receive Royalties
Developing therapies for people with severe neuropsychiatric disorders and pain
Schizophrenia
~2.7M U.S.
Targeting the GI system locally to treat the genesis of chronic disease
EUROPEAN CE MARK GRANTED
Weight management
~150M U.S. (Overweight and obesity)
European CE Mark Granted
Adolescent weight management
~13.7M U.S.
Chronic idiopathic constipation
~35M U.S.
Weight management in type 2 diabetes (T2D)/prediabetes
~30M U.S. (T2D)
~84M U.S. (Prediabetes)
Non-alcoholic steatohepatitis/Non-alcoholic fatty liver disease
~80-100M U.S.
A regenerative platform for hair growth
Androgenetic alopecia
~90M U.S.
Skin rejuvenation
~225K U.S. (Distal colitis)
High-risk Clostridioides difficile
~100-120K/year U.S.
Food allergy
~2.5M U.S. (Peanut allergy)
Inflammatory bowel disease
~3M U.S.
Solid tumors
>46K/year U.S. (Advanced & metastatic MSS CRC)
>11K/year U.S. (Gastric cancers)
>9K/year U.S. (Melanoma)
Depression detection
~17M U.S.
Oral delivery of biologics, vaccines and other drugs
Equity Interest Only
EUROPEAN CE MARK GRANTED
Pediatric ADHD
~6.4M U.S. (Pediatric ADHD)
European CE Mark Granted
Parkinson’s/MCI
Traumatic brain injury
Pediatric autism
~1.5M U.S.
Multiple sclerosis
~900K U.S.
Major depressive disorder
~17M U.S.
Major depressive disorder
~17M U.S.
ADHD caregiver app
1. Funding figure includes private equity financings, public offerings or grant awards. Funding figure excludes upfront payments and future milestone considerations received in conjunction with partnerships and collaborations such as those with Roche, Boehringer Ingelheim, Imbrium Therapeutics L.P., Shionogi & Co., Ltd. or Eli Lilly.
2. Following the completion of a successful End-of-Phase 2 meeting with the U.S. FDA, Karuna remains on track to initiate the Phase 3 program by the end of 2020.
Note: This figure represents the stage of development for each Founded Entity’s most advanced product candidate. While PureTech maintains ownership of equity interests in its Founded Entities, the Company does not, in all cases, maintain control over these entities (by virtue of (i) majority voting control and (ii) the right to elect representation to the entities’ board of directors) or direct the management and development efforts for these entities. Consequently, not all such entities are consolidated in the financial statements. Where PureTech maintains control, the entity is referred to as a Controlled Founded Entity in this report and is consolidated in the financial statements. Where PureTech does not maintain control, the entity is referred to as a Non-Controlled Founded Entity in this report and is not consolidated in the financial statements. As of 31 December 2019, Controlled Founded Entities include Alivio Therapeutics, Inc., Follica, Incorporated, Entrega, Inc., Vedanta Biosciences, Inc. and Sonde Health, Inc., and Non-Controlled Founded Entities include Akili Interactive Labs, Inc., Gelesis, Inc., Karuna Therapeutics, Inc., Vor Biopharma Inc. and, for all periods prior to December 18, 2019, resTORbio, Inc. Relevant ownership interests for Founded Entities were calculated on a diluted basis (as opposed to a voting basis) as of 31 December 2019 (with the exception of Gelesis ownership which is as of 1 April 2020 and Vor ownership which is as of 30 June 2020), including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Ownership of Vor is based on the assumption that all future tranches of the most recent financing round are funded. Karuna ownership is calculated on an outstanding voting share basis as of 26 May 2020.
+ Important Safety Information: Plenity is contraindicated in patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatine, or titanium dioxide. Plenity may alter the absorption of medications. Read Sections 6 and 8.3 of the Instructions for Use carefully. Avoid use in patients with the following conditions: esophageal anatomic anomalies, including webs, diverticuli, and rings; suspected strictures (such as patients with Crohn’s disease); or complications from prior gastrointestinal (GI) surgery that could affect GI transit and motility. Use with caution in patients with active GI conditions such as gastro-esophageal reflux disease (GERD), ulcers or heartburn. The overall incidence of adverse events (AEs) in the Plenity group was no different than the placebo group. The most common side effects were diarrhea, distended abdomen, infrequent bowel movements, and flatulence. For the safe and proper use of Plenity, U.S. Instructions for Use or the EU Instructions for Use.
* These product candidates are regulated as devices and their development has been approximately equated to phases of clinical development.
** Contingent on FDA review of the research plan.
*** Future clinical research plans and priorities in process.
Cash at PureTech Parent Level
$321.5m
PureTech Level Pro-forma Cash Reserves3
$120.6m
PureTech Level Cash Reserves as of December 31, 20194
$45m
Cash from KRTX Equity Sale on May 25, 20205
3. PureTech Level Pro-forma Cash Reserves is an alternative performance measure (APM) which includes the PureTech Level Cash Reserves of $120.6 million and the $200.9 million in proceeds from the 22 January 2020 sale of 2.1 million Karuna common shares. PureTech Pro-forma Cash Reserves is therefore considered to be more representative of the Corporate’s cash available for the year 2020 and beyond to advance product candidates within the full breadth of its operations.
4. PureTech Level Cash Reserves represent cash balances and short-term investments held at PureTech Health LLC, PureTech Management, Inc., PureTech Health PLC, PureTech Securities Corporation of $112.0 million for the year ended 2019 and the internal pipeline of $8.6 million for the year ended 2019, all of which are wholly-owned entities of PureTech, excluding cash balances and short-term investments of Controlled Founded Entities. The balance excludes the $200.9 million in proceeds from the 22 January 2020 sale of 2.1 million Karuna common shares.
5. 44.5 million in proceeds from the 22 May 2020 sale of 555.5 thousand Karuna common shares.
The BIG Idea - Moving medicine forward at PureTech
